- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Endocrinology & Hormones-Targeted Compounds
InquiryOverview
The endocrine system and hormone signaling pathways play a central role in regulating energy metabolism, appetite control, fat storage, and insulin sensitivity. It has been found that obesity may be associated with a variety of endocrine abnormalities caused by changes in the hypothalamic-pituitary hormone axis, including hypothyroidism, hypogonadism, and growth hormone deficiency. Endocrine and hormonal studies are key target areas for understanding the pathophysiological mechanisms of obesity and developing novel therapeutic strategies.
Fig.1 Metabolic and endocrine changes in obesity (Al-Samerria & Radovick, 2023)
Endocrine and Hormone Compound Libraries: Accelerating Your Obesity and Metabolic Disease Research
Protheragen is committed to providing innovative research tools to combat obesity and metabolic diseases. To support and accelerate research in this critical field, we have assembled a specialized compound library featuring structurally diverse, target-specific, high-quality small molecules associated with endocrine and hormone function regulation. This library serves as a powerful screening tool and lead discovery platform for your obesity research projects. These compounds are suitable for endocrine system studies, high-throughput screening, and high-content screening for novel therapeutics targeting endocrine disorders.
Core Advantages and Features
- Highly Targeted: Curated compounds cover key targets in obesity-related endocrine pathways, including but not limited to estrogen receptors, thyroid hormone receptors, and adrenergic receptors, which regulate energy balance, appetite control, insulin signaling, and lipid metabolism.
- Structural Diversity: Incorporates multiple chemical scaffolds, encompassing analogues of known hormones, receptor agonists, antagonists, and synthetic modulators, enhancing opportunities to discover compounds with novel mechanisms of action.
- Comprehensive Information: Detailed chemical structure information, CAS numbers, and purity data are provided for each compound. Where possible, known biological activities and target information are also annotated to facilitate rapid evaluation and selection by researchers.
- Reliable Quality: All compounds undergo rigorous quality control testing (e.g., nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS)) to ensure high purity (typically >95%) and accurate structures, guaranteeing the reliability and reproducibility of experimental results.
- Ready-to-Use Format: Compounds are pre-dissolved in DMSO and supplied in standardized 96-well or 384-well plate formats with uniform concentrations, facilitating high-throughput screening (HTS) and high-content screening (HCS). Customized services are also available upon request.
Applications
- Target Discovery and Validation: Screen compounds that modulate the activity of known or potential endocrine targets and investigate their anti-obesity effects, providing a basis for developing and validating therapeutic targets for obesity.
- Pathway Mechanism Research: Utilizing known active compounds as tools to deeply investigate the mechanisms by which specific hormone signaling pathways contribute to obesity development.
- Lead Compound Discovery: Employing high-throughput screening to identify compounds with potential activity, providing starting points for developing novel anti-obesity drugs or therapies to improve metabolic syndrome.
Advantages
High Relevance
The compound library has been carefully selected by experts in the field of obesity research based on the latest scientific advances to ensure that the compounds are highly relevant to the endocrine pathways involved in obesity.
Quality Assurance
We maintain rigorous quality control processes to ensure the purity and structural accuracy of our compounds. We aim to deliver molecular probes with high reliability and batch-to-batch consistency, thereby minimizing interference from the compounds themselves.
Expert Support
We provide professional technical support and flexible customization services, including guidance on compound selection, optimization of complex experimental protocols, and experimental consultation, to meet your unique research needs.
Publication
Title: Childhood obesity and central precocious puberty
Journal: Frontiers in endocrinology, 2022
DOI: https://doi.org/10.3389/fendo.2022.1056871
Summary: This paper aims to thoroughly examine the roles and mechanisms of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) as potential anti-obesity targets. It specifically analyzes their functions in lipogenesis and lipolysis, as well as their effects on energy balance (such as insulin sensitivity and appetite regulation). Additionally, this paper comprehensively summarizes the evidence regarding the efficacy and safety of developing GH and IGF-1 as therapeutic targets (including drug interventions and hormone replacement therapy), while also thoroughly examining the limitations and challenges encountered along this pathway. These studies provide crucial data support and directional guidance for the future development of safer, more effective anti-obesity therapies.
Fig.2 Intracellular mechanisms of GH regulation and GH receptor (GhR) signaling. (Shi, et al., 2022)
Customer Review
Unparalleled Pathway Coverage
"We systematically evaluated multiple key pathways using Protheragen's endocrine and hormone compound library. This enabled rapid identification of core molecular targets involved in regulation."— Prof. M. R.
Targeted Screening Efficiency
"This library's high focus on endocrine targets yielded significantly higher hit rates compared to generic libraries. Furthermore, Protheragen's comprehensive compound data substantially shortened our lead compound screening cycle."— Dr. O. H.
Frequently Asked Questions
-
Can I purchase only a portion of the compounds in the library? Or order a specific compound individually?
Certainly. We offer flexible customization services. You may select a subset of the library based on your specific research needs, or order individual compounds contained within the library.
-
Who can I contact if I have technical questions or need advice on selecting a compound library?
We have a dedicated technical support team. If you have any questions regarding the use, storage, data interpretation, or selection of compound libraries, please feel free to contact us at any time.
-
Does the compound library provide detailed target specificity data?
Yes, we are committed to providing highly transparent product information. When purchasing the compound library, we will provide a comprehensive electronic data package including compound structures, high-purity verification reports, IC50 values, activity data, and more, enabling researchers to quickly evaluate and design relevant experiments.
Protheragen is committed to delivering the highest quality compound libraries. Through rigorous screening, structural confirmation, and purity testing, we ensure every compound you receive meets stringent standards. We understand the critical importance of rigorous research data and are dedicated to providing the most reliable chemical tools for your studies. Feel free to contact us anytime for further details.
References
- Al-Samerria, S.; Radovick, S. Exploring the therapeutic potential of targeting GH and IGF-1 in the management of obesity: Insights from the interplay between these hormones and metabolism. International journal of molecular sciences. 2023, 24(11): 9556. (CC BY 4.0)
- Shi, L.; et al. Childhood obesity and central precocious puberty. Frontiers in endocrinology. 2022, 13: 1056871. (CC BY 4.0)
Endocrinology & Hormones-Targeted Compounds
- CAS No.: 577-11-7
- Pathways: Endocrinology/Hormones; GPCR/G protein; Neuronal signaling; Microbiology/Virology
- Targets: Opioid receptor
- CAS No.: 519-02-8
- Pathways: Endocrinology/Hormones; GPCR/G protein; Neuronal signaling; Autophagy; Apoptosis
- Targets: G protein-coupled receptors
- Receptors: Opioid receptor; κ-Opioid receptor
- CAS No.: 34552-83-5
- Pathways: Endocrinology/Hormones; Autophagy; Neuronal signaling; GPCR/G protein
- Targets: Opioid receptor
- Receptors: δ-Opioid receptor; κ-Opioid receptor; μ-Opioid receptor
